NASDAQ:AKAO - Achaogen Stock Price, Price Target & More

$13.04 +0.36 (+2.84 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$13.04

Today's Range$12.42 - $13.20

52-Week Range$9.83 - $27.49

Volume1.47 million shs

Average Volume1.22 million shs

Market Capitalization$551.91 million

P/E Ratio-4.11

Dividend YieldN/A

Beta1.04

About Achaogen (NASDAQ:AKAO)

Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Receive AKAO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKAO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:AKAO

CUSIPN/A

Webwww.achaogen.com

Phone650-800-3636

Debt

Debt-to-Equity Ratio0.08%

Current Ratio4.83%

Quick Ratio4.83%

Price-To-Earnings

Trailing P/E Ratio-4.11

Forward P/E Ratio-3.75

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.18 million

Price / Sales52.16

Cash FlowN/A

Price / CashN/A

Book Value$2.88 per share

Price / Book4.53

Profitability

EPS (Most Recent Fiscal Year)($3.17)

Net Income$-125,610,000.00

Net Margins-1,124.10%

Return on Equity-83.14%

Return on Assets-52.31%

Miscellaneous

Employees230

Outstanding Shares44,720,000

How to Become a New Pot Stock Millionaire

Achaogen (NASDAQ:AKAO) Frequently Asked Questions

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen (NASDAQ:AKAO) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.21. The biopharmaceutical company had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.18 million. Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. View Achaogen's Earnings History.

What price target have analysts set for AKAO?

10 brokers have issued 12 month target prices for Achaogen's stock. Their predictions range from $14.00 to $29.00. On average, they expect Achaogen's stock price to reach $23.1250 in the next twelve months. View Analyst Ratings for Achaogen.

What are Wall Street analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

1. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (2/14/2018)
2. Mizuho analysts commented, "We believe the recent price pullback from 52-week highs presents a buying opportunity especially considering Plazomicin represents meaningful advances in the aminoglycoside class with survival benefits ." (11/9/2017)

Who are some of Achaogen's key competitors?

Some companies that are related to Achaogen include Athenex (ATNX), Retrophin (RTRX), Zai Lab (ZLAB), TG Therapeutics (TGTX), CytomX Therapeutics (CTMX), MacroGenics (MGNX), Flexion Therapeutics (FLXN), Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Mirati Therapeutics (MRTX), Amarin (AMRN), Access Pharmaceuticals (ABEO), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Inflarx (IFRX) and Urogen Pharma (URGN).

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

Mr. Blake Wise, CEO & Director (Age 47)
Dr. Kenneth J. Hillan, Pres of R&D, Pres of Achaogen and Director (Age 57)
Dr. Floyd E. Romesberg Ph.D., Principal Scientific Founder and Advisor
Dr. Nathaniel E. David A.B., Ph.D., Principal Entrepreneurial Founder (Age 50)
Mr. Tobin C. Schilke, Chief Financial Officer & Principal Accounting Officer (Age 43)

Has Achaogen been receiving favorable news coverage?

News articles about AKAO stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achaogen earned a news impact score of 0.03 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.42 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Achaogen?

Shares of AKAO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of AKAO stock can currently be purchased for approximately $13.04.

How big of a company is Achaogen?

Achaogen has a market capitalization of $551.91 million and generates $11.18 million in revenue each year. The biopharmaceutical company earns $-125,610,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. Achaogen employs 230 workers across the globe.

How can I contact Achaogen?

Achaogen's mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-800-3636 or via email at [email protected]

MarketBeat Community Rating for Achaogen (AKAO)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		262 (Vote Outperform)
Underperform Votes:		163 (Vote Underperform)
Total Votes:		425

MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe AKAO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKAO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Achaogen (NASDAQ:AKAO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

10 Wall Street analysts have issued ratings and price targets for Achaogen in the last 12 months. Their average twelve-month price target is $23.1250, suggesting that the stock has a possible upside of 77.34%. The high price target for AKAO is $29.00 and the low price target for AKAO is $14.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	2.91	2.90	2.89
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$23.1250	$23.7778	$25.4444	$28.1250
Price Target Upside:	77.34% upside	116.16% upside	128.20% upside	84.31% upside

Achaogen (NASDAQ:AKAO) Consensus Price Target History

Price Target History for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/4/2018	Leerink Swann	Reiterated Rating	Outperform		Low
3/1/2018	HC Wainwright	Lower Price Target	Buy -> Buy	$31.00 -> $29.00	High
2/28/2018	William Blair	Reiterated Rating	Outperform		High
2/28/2018	Stifel Nicolaus	Lower Price Target	Buy -> Buy	$27.00 -> $23.00	Medium
2/28/2018	Needham & Company LLC	Reiterated Rating	Buy -> Buy	$29.00 -> $20.00	Medium
2/14/2018	Wedbush	Reiterated Rating	Positive -> Outperform	$28.00 -> $22.00	High
1/10/2018	Guggenheim	Reiterated Rating	Buy	$14.00	High
1/3/2018	Mizuho	Reiterated Rating	Buy	$28.00	High
1/3/2018	SunTrust Banks	Lower Price Target	Buy	$27.00	High
5/15/2017	Cowen	Reiterated Rating	Outperform		N/A
3/30/2017	Aegis	Downgrade	Buy -> Hold	$29.00	Low

(Data available from 4/19/2016 forward)

Achaogen (NASDAQ:AKAO) Earnings History and Estimates Chart

Earnings by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ:AKAO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.65)
2019 EPS Consensus Estimate: ($3.18)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	($1.00)	($0.85)	($0.93)
Q2 2018	3	($1.02)	($0.96)	($0.99)
Q3 2018	4	($1.01)	($0.77)	($0.89)
Q4 2018	4	($0.91)	($0.81)	($0.85)
Q1 2019	1	($0.85)	($0.85)	($0.85)
Q2 2019	1	($0.81)	($0.81)	($0.81)
Q3 2019	1	($0.78)	($0.78)	($0.78)
Q4 2019	1	($0.74)	($0.74)	($0.74)

Achaogen (NASDAQ AKAO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/27/2018	Q4 2017	($0.77)	($0.98)	$1.18 million	$1.87 million	View	Listen
11/8/2017	Q3	($0.72)	($0.85)	$2.09 million	$0.58 million	View	N/A
8/3/2017	Q2 2017	($0.60)	($0.78)	$2.69 million	$1.30 million	View	Listen
5/8/2017	Q1 2017	($0.54)	($0.93)	$3.81 million	$7.46 million	View	Listen
3/14/2017	Q4 2016	($0.49)	($1.04)	$13.33 million	$10.73 million	View	N/A
11/7/2016	Q3	($0.61)	($0.41)	$8.72 million	$16.05 million	View	Listen
8/8/2016	Q2	($0.67)	($0.87)	$5.58 million	$9.14 million	View	N/A
5/5/2016	Q1 2016	($0.60)	($0.66)	$5.21 million	$5.85 million	View	N/A
3/15/2016	Q414	($0.58)	($0.61)	$5.33 million	$4.70 million	View	Listen
11/5/2015	Q3 2015	($0.46)	($0.48)	$5.10 million	$4.48 million	View	N/A
8/10/2015	Q2 2015	($0.20)	($0.05)	$8.65 million	$12.04 million	View	N/A
5/11/2015	Q1 2015	($0.25)	($0.34)	$5.00 million	$4.88 million	View	N/A
3/16/2015	Q4 2014	($0.33)	($0.27)	$4.96 million	$4.26 million	View	N/A
11/10/2014	Q314	($0.18)	($0.47)	$6.00 million	$4.52 million	View	N/A
8/11/2014	Q2 2014	($0.19)	($0.20)	$5.99 million	$5.20 million	View	N/A
5/12/2014	Q114	($0.21)	($1.00)	$5.39 million	$6.00 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

Achaogen (NASDAQ:AKAO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Achaogen (NASDAQ AKAO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.36%
Institutional Ownership Percentage: 77.37%

Insider Trading History for Achaogen (NASDAQ:AKAO)

Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)

Achaogen (NASDAQ AKAO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2018	Robert W Duggan	Major Shareholder	Buy	47,361	$12.44	$589,170.84	6,411,108
4/2/2018	Robert W Duggan	Major Shareholder	Buy	20,000	$12.51	$250,200.00	6,411,108
3/28/2018	Robert W Duggan	Major Shareholder	Buy	30,000	$12.44	$373,200.00	6,391,108
3/20/2018	Robert W Duggan	Major Shareholder	Buy	36,300	$11.12	$403,656.00	6,336,108
3/15/2018	Robert W Duggan	Major Shareholder	Buy	49,660	$11.36	$564,137.60	6,294,808
3/13/2018	Kenneth J. Hillan	Insider	Sell	2,735	$11.74	$32,108.90
3/12/2018	Robert W Duggan	Major Shareholder	Buy	20,000	$11.39	$227,800.00	6,255,148
3/9/2018	Robert W Duggan	Major Shareholder	Buy	50,000	$11.41	$570,500.00	6,255,148
3/2/2018	Robert W Duggan	Major Shareholder	Buy	527,396	$10.31	$5,437,452.76	5,697,752
2/28/2018	Robert W Duggan	Major Shareholder	Buy	20,000	$10.70	$214,000.00	5,697,752
2/21/2018	Blake Wise	CEO	Sell	1,640	$10.67	$17,498.80
2/21/2018	Kenneth J. Hillan	Insider	Sell	4,606	$10.67	$49,146.02
2/21/2018	Tobin Schilke	CFO	Sell	1,108	$10.67	$11,822.36
2/14/2018	Robert W Duggan	Major Shareholder	Buy	10,000	$10.96	$109,600.00	5,668,310
1/5/2018	Robert W Duggan	Major Shareholder	Buy	50,000	$11.51	$575,500.00	5,617,752
1/3/2018	Robert W Duggan	Major Shareholder	Buy	15,000	$10.89	$163,350.00	5,617,752
12/18/2017	Robert W Duggan	Major Shareholder	Buy	95,012	$11.13	$1,057,483.56	5,602,752
9/26/2017	Blake Wise	COO	Sell	3,576	$15.99	$57,180.24
9/26/2017	Gary Loeb	General Counsel	Sell	1,146	$15.99	$18,324.54
6/12/2017	Tobin Schilke	CFO	Sell	2,066	$21.53	$44,480.98
1/26/2017	Gary Loeb	General Counsel	Sell	521	$16.78	$8,742.38
1/26/2017	Ian Friedland	Insider	Sell	695	$16.78	$11,662.10
1/26/2017	Kenneth J. Hillan	CEO	Sell	1,431	$16.78	$24,012.18
1/26/2017	Tobin Schilke	CFO	Sell	955	$16.78	$16,024.90
1/26/2017	Zeryn Sarpangal	VP	Sell	781	$16.78	$13,105.18
12/19/2016	Equity Opportunities Iv Growth	Major Shareholder	Buy	500,000	$13.50	$6,750,000.00
9/27/2016	Blake Wise	COO	Sell	3,632	$4.30	$15,617.60
9/27/2016	Zeryn Sarpangal	VP	Sell	1,069	$4.30	$4,596.70
3/17/2016	Ian Friedland	Insider	Sell	1,772	$3.22	$5,705.84	32,728
3/17/2016	Kenneth J Hillan	CEO	Sell	3,572	$3.22	$11,501.84	61,628

(Data available from 1/1/2013 forward)

Achaogen (NASDAQ AKAO) News Headlines

Source:

Date	Headline
	An In-Depth Look at Achaogen’s Cash Flow finance.yahoo.com - April 19 at 8:06 AM
	Achaogen’s Financial Performance finance.yahoo.com - April 18 at 5:54 PM
	A Look at Achaogen’s Research Pipeline finance.yahoo.com - April 18 at 5:54 PM
	Q1 2018 EPS Estimates for Achaogen (AKAO) Raised by Analyst www.americanbankingnews.com - April 18 at 7:58 AM
	Analysts Expect Achaogen (AKAO) Will Post Quarterly Sales of $1.25 Million www.americanbankingnews.com - April 18 at 4:32 AM
	Achaogen (AKAO) Forecasted to Post FY2021 Earnings of $1.31 Per Share www.americanbankingnews.com - April 17 at 7:07 AM
	BidaskClub Downgrades Achaogen (AKAO) to Hold www.americanbankingnews.com - April 16 at 9:16 PM
	Specialty Report On Infectious Disease: Unlocking The Upcoming Binary Event Of Achaogen And Value Of Melinta seekingalpha.com - April 16 at 8:06 AM
	Achaogen (AKAO) Expected to Post Earnings of -$0.92 Per Share www.americanbankingnews.com - April 16 at 5:19 AM
	Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious ... globenewswire.com - April 10 at 5:38 PM
	Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) finance.yahoo.com - April 10 at 8:13 AM
	Achaogen (AKAO) Now Covered by Guggenheim www.americanbankingnews.com - April 5 at 9:00 PM
	Insider Buying: Achaogen (AKAO) Major Shareholder Acquires 20,000 Shares of Stock www.americanbankingnews.com - April 4 at 10:57 PM
	Robert W. Duggan Buys 47,361 Shares of Achaogen (AKAO) Stock www.americanbankingnews.com - April 4 at 10:38 PM
	A Billionaire's Latest Biotech Bet www.barrons.com - April 4 at 4:24 PM
	[$$] A Billionaire's Latest Biotech Bet finance.yahoo.com - April 4 at 4:24 PM
	Achaogen (AKAO) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - April 3 at 8:10 PM
	$1.25 Million in Sales Expected for Achaogen (AKAO) This Quarter www.americanbankingnews.com - April 1 at 4:38 AM
	Mizuho Reaffirms "Buy" Rating for Achaogen (AKAO) www.americanbankingnews.com - March 31 at 8:16 PM
	Stifel Nicolaus Cuts Achaogen (AKAO) Price Target to $27.00 www.americanbankingnews.com - March 31 at 7:42 PM
	Form 4 Achaogen Inc For: Mar 28 Filed by: DUGGAN ROBERT W www.streetinsider.com - March 31 at 8:09 AM
	SunTrust Banks Trims Achaogen (AKAO) Target Price to $27.00 www.americanbankingnews.com - March 30 at 11:42 PM
	Insider Buying: Achaogen (AKAO) Major Shareholder Buys 30,000 Shares of Stock www.americanbankingnews.com - March 30 at 10:14 PM
	Achaogen's (AKAO) Buy Rating Reaffirmed at Mizuho www.americanbankingnews.com - March 30 at 10:02 PM
	Edited Transcript of AKAO earnings conference call or presentation 27-Feb-18 9:30pm GMT finance.yahoo.com - March 30 at 5:41 PM
	Brokerages Anticipate Achaogen Inc (AKAO) Will Post Earnings of -$0.92 Per Share www.americanbankingnews.com - March 30 at 8:06 AM
	Research Analysts Set Expectations for Achaogen Inc's FY2022 Earnings (AKAO) www.americanbankingnews.com - March 30 at 7:40 AM
	Zacks Investment Research Lowers Achaogen (AKAO) to Sell www.americanbankingnews.com - March 29 at 9:04 PM
	Guggenheim Reiterates Buy Rating for Achaogen (AKAO) www.americanbankingnews.com - March 29 at 3:00 PM
	Achaogen Inc (AKAO) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - March 28 at 8:08 AM
	2 Small Biotechs That Continue to Look Good finance.yahoo.com - March 25 at 6:32 PM
	Achaogen (AKAO) Price Target Increased to $31.00 by Analysts at HC Wainwright www.americanbankingnews.com - March 25 at 8:16 AM
	Achaogen (AKAO) Given New $29.00 Price Target at HC Wainwright www.americanbankingnews.com - March 24 at 2:12 PM
	Achaogen: Not Too Late To Catch The Rally seekingalpha.com - March 23 at 5:54 PM
	Achaogen: Contrarian Play At An Inflection Point - Seeking Alpha - Seeking Alpha seekingalpha.com - March 23 at 8:08 AM
	Financial Contrast: Achaogen (AKAO) and XBiotech (XBIT) www.americanbankingnews.com - March 23 at 5:32 AM
	Achaogen (AKAO) Says FDA Advisory Committee Meeting for Plazomicin Set for May 2 www.streetinsider.com - March 22 at 5:46 PM
	Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin - GlobeNewswire (press release) globenewswire.com - March 22 at 8:13 AM
	Achaogen Inc (AKAO) Major Shareholder Robert W. Duggan Acquires 36,300 Shares www.americanbankingnews.com - March 21 at 7:32 PM
	Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin finance.yahoo.com - March 21 at 8:26 AM
	Robert W. Duggan Acquires 49,660 Shares of Achaogen Inc (AKAO) Stock www.americanbankingnews.com - March 16 at 7:52 PM
	Insider Selling: Achaogen Inc (AKAO) Insider Sells 2,735 Shares of Stock www.americanbankingnews.com - March 15 at 10:26 PM
	Achaogen Inc (AKAO) Expected to Announce Quarterly Sales of $1.25 Million www.americanbankingnews.com - March 15 at 2:58 PM
	Achaogen to Present at Needham & Company's 17th Annual Healthcare Conference - GlobeNewswire (press release) globenewswire.com - March 15 at 8:06 AM
	Achaogen to Present at Needham & Company’s 17th Annual Healthcare Conference finance.yahoo.com - March 14 at 8:14 AM
	Insider Buying: Achaogen Inc (AKAO) Major Shareholder Purchases 20,000 Shares of Stock www.americanbankingnews.com - March 13 at 8:17 PM
	Robert W. Duggan Buys 50,000 Shares of Achaogen Inc (AKAO) Stock www.americanbankingnews.com - March 13 at 7:34 PM
	Wired News – Cellectar Biosciences to Present Results from Phase-1 Study of CLR 124 Uptake in Brain Tumors at the World Congress of the World Federation of Nuclear Medicine and Biology finance.yahoo.com - March 8 at 8:09 AM
	Achaogen (AKAO) Rating Reiterated by Leerink Swann www.americanbankingnews.com - March 7 at 10:59 AM
	Leerink Swann Weighs in on Achaogen Inc's Q1 2018 Earnings (AKAO) www.americanbankingnews.com - March 7 at 8:16 AM

Achaogen (NASDAQ:AKAO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Achaogen (NASDAQ:AKAO) Income Statement, Balance Sheet and Cash Flow Statement

Achaogen (NASDAQ AKAO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff